CLINICAL AND IMMUNOLOGICAL MARKERS OF DIABETIC FOOT SYNDROME PROGRESSION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Abstract

Diabetic foot syndrome is among the most severe complications of type 2 diabetes mellitus and is associated with a prolonged course of ulcerative-trophic lesions, a high risk of infection, recurrent hospitalizations, and lower-limb amputations

References

1. Armstrong D.G., Boulton A.J.M., Bus S.A. Diabetic foot ulcers and their recurrence // New England Journal of Medicine. 2017. Vol. 376, No. 24. P. 2367–2375.
2. Bus S.A., Lavery L.A., Monteiro-Soares M., et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update) // Diabetes/Metabolism Research and Reviews. 2024. Vol. 40, No. 3. e3651.
3. Ferrara N. VEGF and the quest for tumour angiogenesis factors // Nature Reviews Cancer. 2002. Vol. 2, No. 10. P. 795–803.
4. Garoufalia Z., Papadopetraki A., Karatza E., et al. Insulin-like growth factor-I and wound healing, a potential answer to non-healing wounds: A systematic review and meta-analysis // International Journal of Molecular Medicine. 2021. Vol. 47, No. 6. Article 49.
5. Huang K., Wang Y., Si Z., Zhang Z., Xia Z. Angiogenesis during diabetic wound repair: From mechanism to therapy opportunity // Burns & Trauma. 2025. Vol. 13. tkae052.